AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15627931 — intervention group
Group type: COMPARATOR
Intervention: Control group (no product used)
Number of subjects: 286
Study 11525450 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular allogeneic dermal connective tissue matrix (AD)
Number of subjects: 22
Study 11525450 — intervention group
Group type: COMPARATOR
Intervention: Autogenous palatal connective tissue (CT)
Number of subjects: 22
Study 9764980 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 13
Study 9764980 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-ISDR sequencing
Number of subjects: 13
Study 9764980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide substitution rate
Number of subjects: 13
Study 9764980 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 13
Study 7836526 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (co-cultured with cumulus cells)
Number of subjects: 550
Study 7836526 — intervention group
Group type: COMPARATOR
Intervention: Group B (dissected from cumulus cells)
Number of subjects: 550
Study 2645886 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein test meal
Number of subjects: 23
Study 2645886 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean test meal
Number of subjects: 23
Study 2645886 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein free test meal
Number of subjects: 23
Study 1098580 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin
Number of subjects: 25
Study 1098580 — intervention group
Group type: COMPARATOR
Intervention: Matched control (no heparin)
Number of subjects: 25
Study 31838406 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT + HDTp (Arm A)
Number of subjects: 44
Study 31838406 — intervention group
Group type: COMPARATOR
Intervention: SCT alone (Arm B)
Number of subjects: 44
Study 31219479 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world evidence (RWE)
Number of subjects: 0
Study 28609389 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.45 mg/bazedoxifene 20 mg
Number of subjects: 0
Study 28609389 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg/bazedoxifene 20 mg
Number of subjects: 0
Study 28609389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28609389 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens/MPA 1.5 mg
Number of subjects: 0
Study 26416102 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10(4) PfSPZ in 50 μL/2 doses
Number of subjects: 30
Study 26416102 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10(4) PfSPZ in 10 μL/2 doses
Number of subjects: 30
Study 26416102 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 10(4) PfSPZ in 10 μL/8 doses
Number of subjects: 30
Study 26416102 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 10(4) PfSPZ in eight 10 μL injections
Number of subjects: 30
Study 21504478 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled bars (group I)
Number of subjects: 51
Study 21504478 — intervention group
Group type: EXPERIMENTAL
Intervention: Telescopic crowns (group II)
Number of subjects: 51
Study 21504478 — intervention group
Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 51
Study 20583956 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin monotherapy
Number of subjects: 0
Study 20583956 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study 19095116 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-wave Doppler ultrasound (UTS)
Number of subjects: 31
Study 19095116 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery catheter (PAC)
Number of subjects: 31
Study 16045458 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg cotrimoxazole (CTX)
Number of subjects: 0
Study 16045458 — intervention group
Group type: EXPERIMENTAL
Intervention: 960 mg cotrimoxazole (CTX)
Number of subjects: 0
Study 16045458 — intervention group
Group type: COMPARATOR
Intervention: Unselected cohort from Zomba, Malawi (1995)
Number of subjects: 0
Study 16045458 — intervention group
Group type: COMPARATOR
Intervention: National Tuberculosis Programme (1999)
Number of subjects: 0
Study 11815892 — intervention group
Group type: EXPERIMENTAL
Intervention: Original grading
Number of subjects: 0
Study 11815892 — intervention group
Group type: EXPERIMENTAL
Intervention: Regrading
Number of subjects: 0
Study 11815892 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading for 'confidence of tumor measurement'
Number of subjects: 0
Study 10037245 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 24
Study 10037245 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 7738533 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on Piaget's horizontality task
Number of subjects: 122
Study 7738533 — intervention group
Group type: COMPARATOR
Intervention: Pretest scores
Number of subjects: 122
Study 2210587 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan plus (hyoscine‐N‐butylbromide 30 mg/day + paracetamol 1500 mg/day)
Number of subjects: 712
Study 2210587 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan (hyoscine‐N‐butylbromide 30 mg/day)
Number of subjects: 712
Study 2210587 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1500 mg/day)
Number of subjects: 712
Study 2210587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets/day)
Number of subjects: 712
Study 2210587 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan plus
Number of subjects: 712
Study 2210587 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 712
Study 6786132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 130 ml/kg . min
Number of subjects: 7
Study 6786132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 100 ml/kg . min
Number of subjects: 7
Study 6786132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 70 ml/kg . min
Number of subjects: 7
Study 6786132 — intervention group
Group type: COMPARATOR
Intervention: Conventional semi-closed anaesthesia circuit
Number of subjects: 7
Study 31991116 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI+FaST mapping/ablation
Number of subjects: 80
Study 31991116 — intervention group
Group type: COMPARATOR
Intervention: PVI
Number of subjects: 80
Study 31438489 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded images of favourite food and beverage products
Number of subjects: 48
Study 31438489 — intervention group
Group type: COMPARATOR
Intervention: Unpackaged counterparts of favourite food and beverage products
Number of subjects: 48
Study 28759431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Extracellular Matrix and Compression Therapy
Number of subjects: 1
Study 28759431 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 1
Study 26721139 — intervention group
Group type: EXPERIMENTAL
Intervention: Float needle retention for 6 hours
Number of subjects: 120
Study 26721139 — intervention group
Group type: EXPERIMENTAL
Intervention: Float needle retention for 12 hours
Number of subjects: 120
Study 26721139 — intervention group
Group type: EXPERIMENTAL
Intervention: Float needle retention for 24 hours
Number of subjects: 120
Study 26721139 — intervention group
Group type: COMPARATOR
Intervention: Western medication (75 mg voltaren tablet orally every day for four days)
Number of subjects: 120
Study 23415775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 789
Study 23415775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 789
Study 21859991 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBF 1120 250 mg, twice per day, continuously for 36 weeks
Number of subjects: 83
Study 21859991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 21859991 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBF 1120 250 mg
Number of subjects: 83
Study 19329838 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 17356040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antioxidant therapy (n-acetylcysteine, selenium, vitamin C)
Number of subjects: 43
Study 17356040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 16597660 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed booklets with personalised information from the patient's medical record plus selected general information
Number of subjects: 400
Study 16597660 — intervention group
Group type: COMPARATOR
Intervention: Printed booklets with general information from CancerBACUP
Number of subjects: 400
Study 16597660 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger booklets produced automatically
Number of subjects: 400
Study 16597660 — intervention group
Group type: COMPARATOR
Intervention: Printed booklets produced interactively
Number of subjects: 400
Study 16597660 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed booklets with additional advice on anxiety management
Number of subjects: 400
Study 16597660 — intervention group
Group type: COMPARATOR
Intervention: Printed booklets without additional advice on anxiety management
Number of subjects: 400
Study 12930177 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (R, n = 9)
Number of subjects: 26
Study 12930177 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E, n = 8)
Number of subjects: 26
Study 12930177 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent resistance and endurance training (C, n = 9)
Number of subjects: 26
Study 10751378 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based programme teaching about burns and scalds hazards
Number of subjects: 190
Study 10751378 — intervention group
Group type: COMPARATOR
Intervention: Control school (no intervention)
Number of subjects: 190
Study 10751378 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home exercise
Number of subjects: 190
Study 10751378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall programme effectiveness
Number of subjects: 190
Study 8657760 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid medication
Number of subjects: 30
Study 8657760 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 30
Study 1900101 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 1498
Study 1900101 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 1498
Study 1900101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for encainide)
Number of subjects: 1498
Study 1900101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for flecainide)
Number of subjects: 1498
Study 6439090 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (3 mg)
Number of subjects: 10
Study 6439090 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 31366396 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine during a preliminary 7-day loading phase and for eight consecutive days following a single bout of intense muscle-damaging exercise.
Number of subjects: 0
Study 31366396 — intervention group
Group type: COMPARATOR
Intervention: Placebo during a preliminary 7-day loading phase and for eight consecutive days following a single bout of intense muscle-damaging exercise.
Number of subjects: 0
Study 26897125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnuts (42 g)
Number of subjects: 102
Study 26897125 — intervention group
Group type: COMPARATOR
Intervention: Chocolate (50 g)
Number of subjects: 102
Study 26897125 — intervention group
Group type: COMPARATOR
Intervention: Potato crisps (50 g)
Number of subjects: 102
Study 26897125 — intervention group
Group type: COMPARATOR
Intervention: No added snack food
Number of subjects: 102
Study 25652757 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol 2 mg twice daily
Number of subjects: 44
Study 25652757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (leg compression alone)
Number of subjects: 44
Study 22699838 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-P (1.5 g/kg divided twice per day for 2 days)
Number of subjects: 30
Study 22699838 — intervention group
Group type: COMPARATOR
Intervention: Senna (15 mL daily for ages 6-12 or 30 mL daily for ages 12-21 for 2 days)
Number of subjects: 30
Study 21362056 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent strength and endurance (SE) training
Number of subjects: 14
Study 21362056 — intervention group
Group type: COMPARATOR
Intervention: Endurance (E) training
Number of subjects: 14
Study 19563006 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative administration of celecoxib (200 mg twice daily, starting 3 days before TKA and extending to 5 days postoperatively)
Number of subjects: 60
Study 19563006 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative administration of celecoxib
Number of subjects: 60
Study 19563006 — intervention group
Group type: COMPARATOR
Intervention: Control group (postoperative administration of celecoxib, 200 mg twice daily, starting 2 hours after TKA and extending to 5 days postoperatively)
Number of subjects: 60
Study 19563006 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 16405543 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 61
Study 16405543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 15546434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat plant sterol ester (PSE)‐enriched spread (21 g day(‐1))
Number of subjects: 48
Study 15546434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11342469 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) using gadolinium-diethylenetriamine pentaacetic acid bismethylamide (Omniscan; 0.1 mmol/kg injected at 3 mL/s IV) during hyperemia (dipyridamole 0.56 mg/kg)
Number of subjects: 48
Study 11342469 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR)
Number of subjects: 48
Study 11342469 — intervention group
Group type: COMPARATOR
Intervention: Positron Emission Tomography (PET)
Number of subjects: 48
Study 11342469 — intervention group
Group type: COMPARATOR
Intervention: Quantitative Coronary Angiography
Number of subjects: 48
Study 9246252 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment focusing on sexual dysfunction
Number of subjects: 69
Study 9246252 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment focusing on interpersonal problems
Number of subjects: 69
Study 9246252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both sexual dysfunction and interpersonal problems
Number of subjects: 69
Study 9246252 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 69
Study 8280561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance
Number of subjects: 40
Study 8280561 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane induction and maintenance
Number of subjects: 40
Study 8280561 — intervention group
Group type: COMPARATOR
Intervention: Enflurane anaesthesia without hypotension (Control)
Number of subjects: 40
Study 3518552 — intervention group
Group type: COMPARATOR
Intervention: Protocol I (0 mg fentanyl)
Number of subjects: 159
Study 3518552 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol II (0.05 mg fentanyl)
Number of subjects: 159
Study 3518552 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol III (0.1 mg fentanyl)
Number of subjects: 159
Study 3518552 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol IV (0.15 mg fentanyl)
Number of subjects: 159
Study 31157949 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz high frequency stimulation (HFS)
Number of subjects: 99
Study 31157949 — intervention group
Group type: COMPARATOR
Intervention: Lower frequency stimulation (LFS) below 1500 Hz
Number of subjects: 99
Study 31157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial success rate
Number of subjects: 99
Study 31157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with predominant low back pain
Number of subjects: 99
Study 31157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with leg pain ≥ low back pain
Number of subjects: 99
Study 31157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection rate
Number of subjects: 99
Study 31157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal and explantation
Number of subjects: 99
Study 31157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode migrations
Number of subjects: 99
Study 30281796 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MAT-sf scores
Number of subjects: 1574
Study 28803119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity cycling (∼40%HRR) for 15 minutes
Number of subjects: 24
Study 28803119 — intervention group
Group type: COMPARATOR
Intervention: Control condition (sitting quietly on the bike for 15 minutes)
Number of subjects: 24
Study 24630745 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary occupational and sport therapy intervention for dementia patients suffering from apathy, provided once a week for 10 months.
Number of subjects: 117
Study 24630745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 117
Study 22733197 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic left hemicolectomy with preservation of the inferior mesenteric artery (IMA)
Number of subjects: 107
Study 22733197 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic left hemicolectomy with IMA sectioned below the left colic artery
Number of subjects: 107
Study 21209618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 32
Study 21209618 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 32
Study 18080713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic balloon dilatation
Number of subjects: 53
Study 18080713 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 53
Study 16752834 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cell transplantation (more than 1 X 10(8)) in group A
Number of subjects: 22
Study 16752834 — intervention group
Group type: COMPARATOR
Intervention: Control group (less than 1 X 10(5)) in group B
Number of subjects: 22
Study 12854148 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine+interferon
Number of subjects: 34
Study 12854148 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 34
Study 12854148 — intervention group
Group type: COMPARATOR
Intervention: interferon
Number of subjects: 34
Study 12652617 — intervention group
Group type: EXPERIMENTAL
Intervention: all-trans-retinoic acid (ATRA) at a dosage of 25 mg/m(2)/day
Number of subjects: 14
Study 10853849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,250 mg azithromycin
Number of subjects: 12
Study 10853849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8661791 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon coagulation
Number of subjects: 24
Study 8661791 — intervention group
Group type: COMPARATOR
Intervention: Standard electrocoagulation
Number of subjects: 24
Study 1991527 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (OC, 7‐7‐7)
Number of subjects: 1259
Study 1991527 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to monophasic pill (1/35)
Number of subjects: 1259
Study 1991527 — intervention group
Group type: COMPARATOR
Intervention: Control group (various OCs)
Number of subjects: 1259
Study 1991527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5/35 monophasic pill
Number of subjects: 1259
Study 1991527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/35 monophasic pill
Number of subjects: 1259
Study 6826814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (twice daily)
Number of subjects: 70
Study 6826814 — intervention group
Group type: COMPARATOR
Intervention: Dicloxacillin (four times daily)
Number of subjects: 70
Study 31362541 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management (n=31)
Number of subjects: 60
Study 31362541 — intervention group
Group type: COMPARATOR
Intervention: Medical management (n=29)
Number of subjects: 60
Study 31362541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 30015146 — intervention group
Group type: EXPERIMENTAL
Intervention: Males + estrogenized females (EFEM-MAR)
Number of subjects: 92
Study 30015146 — intervention group
Group type: EXPERIMENTAL
Intervention: Males + estrogenized females (EFEM-APR)
Number of subjects: 92
Study 30015146 — intervention group
Group type: COMPARATOR
Intervention: Males + non-treated-anestrous females (CONT-MAR)
Number of subjects: 92
Study 30015146 — intervention group
Group type: COMPARATOR
Intervention: Males + non-treated-anestrous females (CONT-APR)
Number of subjects: 92
Study 26818376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (one stick of sugarless gum during the pause interval of drinking polyethylene glycol solution)
Number of subjects: 131
Study 26818376 — intervention group
Group type: COMPARATOR
Intervention: Control group (drank polyethylene glycol solution according to the general protocol)
Number of subjects: 131
Study 26818376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 131
Study 25066331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 mg per day tapered) and fludrocortisone (50 μg tablet once per day)
Number of subjects: 336
Study 25066331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 25066331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and fludrocortisone
Number of subjects: 336
Study 23202523 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI-05 vaccine (15, 45, and 90 µg) with Alhydrogel® (0.75 mg aluminum per dose)
Number of subjects: 0
Study 23202523 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI-05 vaccine (90 µg) without Alhydrogel®
Number of subjects: 0
Study 23202523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20214068 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding at Baihui (GV 20), Shenting (GV 24), Sishencong (EX-HN 1) combined with massage of sole
Number of subjects: 49